Treatment
Participants will be randomized (1:1):
- Mirvetuximab Soravtansine + Prednisolone acetate ophthalmic suspension 1% eye drops
- Mirvetuximab Soravtansine + Brimonidine tartrate ophthalmic solution eye drops
Treatment duration
The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.
Eligibility
Main inclusion criteria:
- FRα positive tumor (centrally tested)
Main exclusion criteria:
- Grade 2 or higher peripheral neuropathy
- Significant active or chronic corneal disorders, history of corneal transplantation, significant ocular inflammatory conditions or other active ocular conditions
- Prior treatment with mirvetuximab Soravtansine or other FRα-targeting agents
Disclaimer: This is an overview of the main in- and exclusion criteria which can also be found on clinicaltrials.gov (NCT06365853). Criteria might change during the course of the study due to amendments. Inclusion in the trial remains the responsibility of the principal investigator of the trial and will depend on patient eligibility and slot availability.
Contact
In case you feel your patient might be eligible for this trial or in case you want to have more information about this trial, please feel free to contact us via: lgog@uzleuven.be